Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Staphylococcal surface receptors, primarily belonging to the Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMM) family, are essential virulence factors anchored to the cell wall of Staphylococcus aureus (Foster et al., 2014). These receptors, which include Protein A (Spa), Clumping factor A (ClfA), and Fibronectin-binding proteins (FnbpA/B), mediate the critical first step of infection by adhering to host extracellular matrix proteins like fibrinogen, collagen, and fibronectin (Speziale et al., 2009). Beyond simple attachment, these proteins facilitate immune evasion; for example, Protein A binds the Fc region of host antibodies to prevent opsonization and subsequent phagocytosis (Foster et al., 2014). Due to their surface exposure and vital roles in pathogenesis, they are primary targets for the development of passive and active immunotherapies, such as the monoclonal antibody Tefibazumab and the IsdB-targeting vaccine V710 (PubMed, 2023). However, the high degree of functional redundancy and genetic diversity among these surface receptors across different clinical isolates remains a major hurdle for achieving broad therapeutic efficacy (Nature Reviews Microbiology, 2014).
Inhibition of bacterial adhesion to host tissues, neutralization of immune evasion mechanisms, and promotion of opsonophagocytic clearance by the host immune system.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Staphylococcal surface protein (MSCRAMM).